Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Windtree Therapeutics Inc (WINT)
Windtree Therapeutics Inc (WINT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Windtree Therapeutics (NASDAQ: WINT) Granted EU Patent for SERCA2a Activator Therapy for Heart Failure

Windtree Therapeutics, Inc. (NASDAQ: WINT) is engaged as a biotechnology company, which is focused on late-stage treatments for cardiovascular disorders.

WINT : 0.3895 (+8.19%)
Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why

Windtree Therapeutics, Inc. (WINT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

WINT : 0.3895 (+8.19%)
Pre-Market Brief: Stocks Mixed as Bond Yields Rebound

December S&P 500 futures (ESZ22) are trending lower -1.15% this morning, erasing yesterday’s gains after three major US benchmark indices bounced back sharply during the regular session as risk appetite...

ESZ22 : 3,871.47s (-0.66%)
HMB.S.DX : 141.260 (+0.67%)
WINT : 0.3895 (+8.19%)
AMPS : 6.89 (+1.17%)
FSLR : 158.05 (+2.70%)
SUNL : 0.2200 (unch)
CNXA : 0.2899 (-3.43%)
Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value

Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE NEWSWIRE)...

WINT : 0.3895 (+8.19%)
Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid

The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better...

WINT : 0.3895 (+8.19%)
Windtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference

Company to host conference call following the presentation...

WINT : 0.3895 (+8.19%)
Suspense Builds over Canadian Jobs Numbers Next Week

Monday U.S. Economic Lookahead Factory orders (Feb.) Featured Earnings Silverback Therapeutics ...

SBTX : 5.87 (+1.03%)
WINT : 0.3895 (+8.19%)
MYSZ : 0.3999 (+1.81%)
LNN : 120.50 (+1.00%)
GBX : 52.56 (+1.57%)
SGH : 22.52 (+5.88%)
RPM : 114.77 (-0.50%)
LEVI : 18.24 (+0.39%)
SMPL : 35.15 (-0.93%)
STZ : 250.00 (+0.60%)
CAG : 27.78 (-1.07%)
LW : 102.05 (-0.16%)
Windtree to Participate in the Lytham Partners Spring 2022 Investor Conference

Company to present on Monday, April 4, 2022 at 11:00 am...

WINT : 0.3895 (+8.19%)
Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple...

WINT : 0.3895 (+8.19%)
Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury

Results support the feasibility for development of a potential treatment for critically ill patients with ARDS due to COVID-19 and other causes...

WINT : 0.3895 (+8.19%)

Barchart Exclusives

Gold: Is $2,000 a Bottom?
Gold reached a new record high in 2023 and was the only precious metal with a significant gain last year. While the $2,000 level was a technical resistance level over the past years, it has become technical support in 2024. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar